Advertisement

FDA: Group of teething products may pose health danger to babies

The agency said to stop using products containing benzocaine for teething because the drug can cause methemoglobinemia, a condition that greatly reduces the level of oxygen carried through the blood.

By HealthDay News
Rather than using benzocaine-containing products to control the pain of teething, experts suggest a firm plastic, but not frozen, or massaging the gums gently with a finger. Photo by collusor/Pixabay
Rather than using benzocaine-containing products to control the pain of teething, experts suggest a firm plastic, but not frozen, or massaging the gums gently with a finger. Photo by collusor/Pixabay

WEDNESDAY, May 23, 2018 -- Consumers should stop using over-the-counter teething products that contain benzocaine because they pose a serious health threat to infants and young children, U.S. health officials warned Wednesday.

Benzocaine can cause a serious health threat called methemoglobinemia, which greatly reduces the level of oxygen carried through the blood. The condition is potentially fatal, the U.S. Food and Drug Administration said in a news release.

Advertisement

Benzocaine is marketed as a way to ease the pain of a variety of oral health problems, including teething, sore throat, canker sores, and irritation of the mouth and gums. Products containing benzocaine are sold as gels, sprays, ointments, solutions and lozenges under such over-the-counter brand names Anbesol, Baby Orajel, Cepacol, Chloraseptic, Hurricane, Orabase, Orajel and Topex, the FDA said. There are also store brands and generics containing the compound.

The FDA said parents and caregivers should stop using the products and companies should stop selling them. If the manufacturers don't comply with the order, the agency said it would take the necessary steps to remove the products from the market.

"Given the accumulating evidence regarding benzocaine's association with methemoglobinemia, we are taking necessary action to work with industry to discontinue the distribution and sale of over-the-counter benzocaine oral health products intended for teething pain," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Advertisement

Signs and symptoms of methemoglobinemia may set in after using benzocaine for the first time, and could appear within minutes to 1 to 2 hours. Symptoms include pale, gray- or blue-colored skin, lips and nail beds; shortness of breath; fatigue; headache; lightheadedness; and rapid heart rate. If any of these symptoms occur, the child should receive immediate medical care, the FDA said.

And, as always, store all drug products where children can't reach them, the agency said.

To treat teething pain, the FDA suggests following recommendations from the American Academy of Pediatrics. The recommendations include using a teething ring made of firm rubber (but not frozen), or to gently rub or massage the child's gums with a finger.

Pain relievers and medications that are rubbed on the gums for teething don't work because they wash out of a baby's mouth within minutes and may present safety concerns, the FDA said.

More information

To learn more about treating teething pain, visit the American Academy of Pediatrics.

Copyright © 2018 HealthDay. All rights reserved.

Latest Headlines